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Introduction. Lung cancer is the most common cancer in the world. Every year, there are over 1.4 million new cases 
and about 1.3 million deaths due to lung cancer. Data on the results of palliative treatment of patients with non-small 
cell lung cancer in Poland are scarce.
Methods. The results of first-line palliative chemotherapy in 204 lung cancer patients treated in the period 2011–2014 
in two cancer centres were analysed.
Results. The mean age of the study group was 63.4 ± 8.3 years; 155 patients received chemotherapy with cisplatin, 
33 — schemes containing carboplatin, 8 — inhibitors of EGFR tyrosine kinase, 8 — vinorelbine or gemcitabine mo-
notherapy. Complete regression was observed in 2 patients, partial response — in 52 patients (25%), stable disease 
in 92 (45%) and 58 (28%) patients had progression. Median survival for the entire group of patients was 12 months. 
Multidrug chemotherapy with cisplatin compared with chemotherapy involving carboplatin monotherapy was 
associated with increased toxicity in total (p = 0.04). An increased toxicity concerned only to haematological compli-
cations and renal insufficiency expressed by the level of creatinine in blood serum. There was no apparent effect of 
chemotherapy on the overall quality of life.
Conclusions. The results of palliative treatment of non-small cell lung cancer in daily practice are comparable to those 
obtained in prospective clinical trials despite having a different population of treated patients. The use of palliative 
chemotherapy had no significant effect on quality of life.
NOWOTWORY J Oncol 2017; 67, 1: 24–33
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Introduction 
Lung cancer is the most common cancer in the world. 
Each year, there are more than 1.4 million new cases and 
about 1.3 million deaths due to lung cancer are recorded [1]. 
Admittedly, in the case of men, these figures have ceased to 
grow for some time. That said, in many places of the world 
(including Poland), the number of cases of adenocarcinoma 
in both sexes and all types of lung cancer in women has 
been increasing. According to the National Cancer Regis-
ter, in Poland about 21,000 new cases of lung cancer are 
diagnosed annually with almost 15,000 among men and 
more than 6,000 in women [2]. Non-small cell lung cancer 
(NSCLC) makes up about 80–85% of all primary cancers of 
the respiratory tract in Poland [2].
In spite of some improvements in early diagnostics and 
treatment in recent decades, the prognoses in lung cancer 
still remains poor. In Poland, only about 11.9% men and 
16.9% women survive five years with the majority of them 
being treated only palliatively already from the moment of 
their diagnosis [2, 3]. In spite of significant development and 
progress in molecular therapies and new chemotherapeutic 
agents, patients with metastatic lung cancer practically 
cannot be cured. Patients with NSCLC with IIIB and IV have 
particularly poor prognoses. In the last decade, the me-
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dian overall survival of the patients with metastatic NSCLC 
treated systemically within clinical studies, have grown from 
a few months to more than 20 months as reported in some 
studies results [4–7]. This improvement was obtained thanks 
not only to the modification of the previous treatment regi-
mens [8–11], but first of all thanks to the application of new 
drugs, such as epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKI) and ALK inhibitors [12–20].
The data concerning palliative treatment of lung can-
cer patients in Poland are scarce. The data concerning the 
toxicity of treatment and life quality of the patients are also 
missing. This study, comprising a large group of patients 
undergoing systemic treatment within everyday clinical 
practice, forms an attempt to evaluate the real efficiency 
of treatment within this population, taking into considera-
tion the therapeutic possibilities within the reimbursement 
programme of the National Health Fund. An attempt to 
determine the factors affecting the overall survival of the 
patients was also made. 
Material and methods
The study concerned 204 patient with non-resectable, 
metastatic NSCLC (ICD10 = C34), who, in the period between 
2011 and 2014 were treated with first-line chemotherapy 
in the Specialist Hospital in Wejherowo and in the Regional 
Oncology Centre in Gdansk. This group was made up of 
patients with primary or secondary cancer spread, who 
were not qualified for an attempt at radical treatment. The 
clinical data was obtained from the source documentation 
— patient information charts. In total, the files of 210 were 
analysed, and the documents of 6 patients were excluded 
from further analysis on account of incomplete data.
The analysis concerned the age, gender, educational 
status, smoking and family history, body height and weight, 
pain intensity, histopathological diagnosis, EGFR evaluation 
and the treatment regimen applied. Smokers were defined 
as those who smoked at least one cigarette per day within 12 
months. A positive family history in lung cancer was defined 
as lung cancer among the relatives with first and second 
degree of consanguinity. These data were obtained from 
patients on the basis of interviews. The body weight and 
height of each patient was registered at the moment of com-
mencement of treatment. The response was evaluated with 
the RECIST 1.1 scale, always on the basis of CT examination.
The analysis also concerned the data on treatment toxic-
ity classified according to WHO (World Health Organization) 
criteria, observed on the first day of the consecutive chemo-
therapy cycle, irrespectively of its regimen. Haematological 
toxicity was evaluated on the basis of the laboratory tests 
performed on the day of the planned administration of 
chemotherapy. Other adverse events were analysed on 
the basis of the medical records kept by a doctor in charge 
of a case.
The quality of life was evaluated on the basis of the 
EORTC QLQ-C30 questionnaire [21]. The questionnaires in 
the Polish language version were filled in by the patients 
on the last week preceding the commencement of chemo-
therapy and in the first week after its completion. 
For the analysis of the results, some basic descriptive 
statistic techniques were used. Arithmetic means were com-
pared with the use of the t-Student test in the case of two 
variables and on the basis of the ANOVA analysis for more 
than two variables. The evaluation of the relationship of the 
demographic and clinical data and the response to treat-
ment was made with logistic regression. The influence of 
specific factors on the overall survival was evaluated with 
the use of Cox proportional hazard regression with the 
likelihood ratio test. A value below p = 0.05 was regarded 
as statistically significant. 
In the evaluation of the quality of life, detailed instruc-
tions provided by EORTC were taken into consideration. 
The statistical processing was made with Microsoft Excel 
software and the PQSTAT software, version 1.4. The study 
received the consent of the directors of both institutions 
and the Ethical Committee at the Regional Medical Cham-
ber in Gdansk. The condition to receive the consent was 
the presentation of the database observing the complete 
confidentiality of the patients’ data.
Results
The patients’ details are presented in Table I. The mean 
age of the study group was 63.4 ± 8.3 years, and the me-
dian age was 65 years; 13% of the patients was made up of 
patients above 70 years of age; 64% were men; 78% were 
patients with dissemination of the primary tumour; 90% of 
the groups were previous or current tobacco smokers. The 
most frequent histological subtype was adenocarcinoma 
(46.6%) and squamous cell carcinoma (41.6%). The EGFR mu-
tation was determined in 98 cases and found in 10 of them. 
In the first line of treatment, the therapy with epidermal 
growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) 
was used in 8 cases, whereas, in the second line — in one 
case, whilst in another case, in spite of the identification of 
the EGFR mutation, this therapy was not applied on account 
of uncontrolled metastases to the central nervous system. 
In 155 cases, chemotherapy regimens with cisplatin 
were used, and in 33 cases — with carboplatin, whereas 
in the remaining 8 cases — vinorelbine or gemcitabine 
in monotherapy. The applied treatment regimen had no 
relationship with the performance status (p = 0.17), sex 
(p = 0.19), patients’ educational status (p = 0.19), place of 
residence (p = 0.15), smoking status (p = 0.69) and primary 
or secondary metastases of the tumour (p = 0.97). Some 
relationship was found between the choice of monotherapy 
and the choice of the carboplatin regimens and the age of 
the subjects (p < 0.01). Carboplatin was more frequently 
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applied in the elderly patients. Monotherapy was used in all 
patients above 75 and whose performance status was = 2. 
In the case of the adenoma diagnosis, giant-cell carci-
noma of the lung (GCCL) or a cancer with the predominance 
of the above-named histological subtypes, treatment by 
pemetrexed in the first line of therapy was applied in 21 
cases. 
Complete regression was obtained in 2 cases (one case 
of chemotherapy based on cisplatin and one case of treat-
ment with the tyrosine kinase inhibitor). A partial response 
was obtained in 52 cases (25.5%), stabilisation in 92 cases h 
(45.1%), whist in 58 cases (28.4%) progression of the disease 
was observed.
In multiple factor analysis of variance (logistic regres-
sion), the response to treatment (complete and partial) with 
the use of cisplatin was not related to the analysed factors. 
However, a tendency towards higher probability of obtain-
ing response to treatment was observed once pemetrexed 
was added to cisplatin (Tab. II). For carboplatin, the number 
of cases did not meet the statistical objectives for multiple 
factor analysis of variance.
Out of 204 analysed cases, 3 patients were still alive 
at the moment of the analysis. The median of overall sur-
vival in the entire group was 12.1 months. In the multiple 
factor analysis of variance, the overall survival period was 
affected by the performance status (PS = 0 contributed 
to a longer survival), treatment regimen (longer survival 
in cisplatin therapy) and the reported response to treat-
ment (Tab. III). The median of overall survival for patients 
treated with cisplatin was 12.1 months (after the addition 
of pemetrexed — 12.7 months); for the patients treated 
with carboplatin — 10.6 months; for monotherapy — 10.2 
months; the therapy with epidermal growth factor receptor 
tyrosine kinase inhibitors — 21.2 months. The median over-
all survival for adenocarcinoma was 12.6 months and did not 
differ significantly from the median overall survival for other 
types of non-small cell lung cancer (11.9 months; p = 0.22). 
Second line therapy was applied in 139 subjects (68%). 
35 patients did not receive the second line of chemotherapy 
on account of their poor general condition; 21 patients — 
on account of the fast progression and very short expected 
survival period, the further course of treatment of 8 patients 
remains unknown, whilst one of the patient refused further 
treatment. The second line of chemotherapy was used only 
in one patient who, in the first line, was treated with mono-
therapy. If, in the first line of chemotherapy, drugs with platin 
were used, the patients in the second line of treatment, 
received monotherapy with docetaxel (n = 89), pemetrexed 
(n = 18), gemcitabine (n = 19) and vinorelbine (n = 12) and 
anti-EGFR therapy (n = 1).
The survival period in the patients who received one 
line of treatment was shorter in comparison with those who 
received some consecutive lines of therapy (median survival: 
9.9 and 12.9 months respectively; p < 0.01). The overall 
survival period in the case of patients receiving pemetrexed 
in the first or second line of treatment was similar in com-
parison with patients treated without this agent (median 
survival: 12.5 and 12.0 months respectively, p = 0.33). The 
median overall survival of the patients who, in the second 
line of treatment were receiving docetaxel was 12.1 months. 
Table I. Patient’s details 
Feature Number
Performance score
0
1
2
108 (53%)
80 (39%)
16 (8%)
Distant metastases
yes
no
178 (87%)
26 (13%)
Age (years)
41–50
51–60
61–70
> 70
19 (9%)
62 (30%)
96 (47%)
27 (13%)
Sex 
women 
men
73 (36%)
131 (64%)
Histological type
adenocarcinoma 
squamous cell carcinoma 
other 
unknown
93 (46.6%)
85 (41.7%)
13 (6.4%)
13 (6.4%)
EGFR mutation 
present 
absent 
not checked 
10 (4.9%)
88 (43.1%)
108 (53.0%)
Lung cancer in the family 
yes
no
18 (9%)
186 (91%)
Place of residence
urban areas
rural areas
135 (66%)
69 (34%)
Smoking history 
yes
no
184 (90%)
20 (10%)
Educational status
lower than secondary 
secondary 
higher 
70 (34%)
72 (35%)
62 (30%)
Cancer spread
primary 
secondary 
159 (78%)
45 (22%)
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The most frequent adverse events in the chemotherapy 
group were haematological toxicity, including neutropenia, 
thrombocytopaenia and anaemia, as well as peripheral neu-
ropathy, vomiting and diarrhoea (Tab. IV). Adverse events 
which occurred more rarely comprised infections, hair loss, 
fatigue and constipation. General toxicity was not related to 
the performance status (p = 0.13), sex (p = 0.67), educational 
status (p = 0.25), place of residence (p = 0.76), smoking status 
(p = 0.17), primary or secondary metastases (p = 0.85), diabe-
tes (p = 0.09), arterial hypertension (p = 0.35) and response 
to treatment (p = 0.89). General toxicity depended on the 
type of chemotherapy (monotherapy in comparison with 
multi-drug regimens; p < 0.01) and age (above and below 
70 years of age; p < 0.01). Also a significant difference in 
general toxicity was observed in the groups receiving 
chemotherapy based on varied platin derivatives (cisplatin 
vs carboplatin; p = 0.04). The risk of toxicity was higher in 
the group treated with cisplatin. Higher toxicity of chemo-
therapy based on cisplatin concerned solely haematological 
complications and an increase of creatinine level in blood 
serum. Moreover, in two cases, a deterioration in audiomet-
ric hearing was documented. Other toxicity profiles were 
observed in the case of inhibitors of EGFR tyrosine kinase 
(Tab. IV).
Table II. The impact of demographic and clinical factors on response to cisplatin (multivariate analysis)
–95% CI +95% CI Statistical value P value
Performance score –0.89207 0.499571 0.305573 0.58041
Pemetrexed addition –3.91701 0.324714 2.755215 0.096938
Age –0.07819 0.021592 1.235977 0.266248
Sex –0.81292 0.735198 0.009682 0.921616
Histopathological type –0.43621 0.778585 0.305138 0.580679
Presence of distant metastases –0.6217 2.253003 1.237026 0.266045
Table III. The impact of demographic and clinical factors on overall survival (multivariate analysis)
–95% CI +95% CI stat. t P value
Performance score –2.82465 –0.79149 –3.50796 0.000562
Pemetrexed addition –1.35659 2.973976 0.73663 0.462242
Age 0.054997 1.821152 2.095165 0.037461
Sex –0.08897 0.068761 –0.25266 0.800799
Histopathological type –0.81468 0.688952 –0.16491 0.869186
Presence of distant metastases 5.159973 8.092461 8.913318 <0.000001
Table IV. The frequency of side effects according to chemotherapy regimen. Significant differences marked in bold 
Toxicity The share of toxicity level 3. and 4.
erlotinib/gefitinib cisplatin carboplatin monotherapy
Vomiting 0/8 22/155 2/33 1/8
Diarrhoea 1/8 15/155 3/33 1/8
Infections 0/8 6/155 1/33 0/8
Anaemia 0/8 34/155 1/33 0/8
Thrombocytopaenia 0/8 20/155 1/35 0/8
Neutropenia 0/8 51/155 3/33 0/8
Neuropathy 0/8 7/155 0/33 0/8
Nephrotoxicity* 0/8 19/155 1/33 0/8
Dermal toxicity and dry cornea 2/8 1/155 0/33 0/8
Ototoxicity 0/8 2/155 0/33 0/8
*defined as an increase of creatinine level above referential values 
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Table V. Results of palliative treatment of patients with NSCLC in phase III trials since 2000 (detailed data and references available from the authors)
The first author Year Primary endpoint OS (months) Number of patients
Sculier JP 2000 OS 8 297
Gatzemeier U 2000 OS 8.6 414
Ranson M 2000 OS 6.8 157
Frasci G 2000 OS 7 120
Fossella FV 2000 OS 8.5 373
Comella P 2000 OS 11.5 180
von Pawel J 2000 OS 8.5 438
Bonomi P 2000 Qol, OS 9.9 599
Shepherd FA 2000 OS 7 103
Sandler AB 2000 OS 9.1 522
Vansteenkiste JF 2001 RR 7.2 169
Kelly K 2001 OS 8 408
Smith IE 2001 OS 7 308
Souquet PJ 2002 OS 10 259
Scagliotti GV 2002 RR 9.8 607
Rosell R 2002 RR 9.8 618
Kosmidis P 2002 OS 10.4 509
Sculier JP 2002 OS 8.2 280
Socinski MA 2002 Qol, OS 8.9 230
Schiller JH 2002 OS 7.9 1155
Smit EF 2003 OS 8.9 480
Wachters FM 2003 OS 10.5 240
Belani CP 2003 RR, TTP 10.1 390
Danson S 2003 OS 8.8 372
Fossella F 2003 OS 11.3 1218
Gridelli C 2003 Qol 9.5 503
Gridelli C 2003 OS 9 707
Negoro S 2003 OS 12 398
Comella P 2004 OS 9.7 264
Georgoulias V 2004 OS 10.5 319
Stathopoulos GP 2004 OS 11 360
Laack E 2004 OS 8.5 300
O’Brien ME 2004 OS 8 419
Herbst RS 2004 OS 9.9 1037
Giaccone G 2004 OS 10.9 1093
Kubota K 2004 OS 11.3 302
Williamson SK 2005 OS 11 367
Sederholm C 2005 OS 10.3 325
Herbst RS 2005 OS 10.6 1059
Belani CP 2005 OS 9.8 369
Leighl NB 2005 OS 9.2 774
Pujol JL 2005 PFS 11.1 311
Georgoulias V 2005 OS 9.7 413
Bissett D 2005 OS 11.5 362
Lilenbaum RC 2005 OS 8.8 561
Rudd RM 2005 OS 10 422
Martoni A 2005 OS 11 272
Æ
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The first author Year Primary endpoint OS (months) Number of patients
Westeel V 2005 OS 11.9 566
Sandler A 2006 OS 12.3 878
von Plessen C 2006 Qol. OS 8 297
Kudoh S 2006 OS 14.3 180
Ramlau R 2006 OS 7.5 829
Booton R 2006 OS 9.5 433
Paz-Ares L 2006 OS 10.4 670
Paccagnella A 2006 OS. RR 10.8 319
Park JO 2007 OS 15.9 314
Hainsworth JD 2007 OS 8 345
Helbekkmo N 2007 OS 7.3 432
Gridelli C 2007 OS 11.5 240
Gatzemeier U 2007 OS 11 1159
Sculier JP 2007 OS 11.9 281
Novello S 2007 OS 13 250
Ohe Y 2007 OS 13.9 581
Comella P 2007 OS 10.7 433
Kosmidis PA 2008 OS 10.49 452
Kubota K 2008 OS 14.1 393
Scagliotti GV 2008 OS 10.8 1669
Ramlau R 2008 OS 12.3 623
Blumenschein GR Jr 2008 OS 12.4 612
Belani CP 2008 OS 9.5 444
Kosmidis PA 2008 OS 10.49 452
Reynolds C 2009 OS 6.7 170
Lee SM 2009 OS 8.9 720
Ciuleanu T 2009 PFS 13.4 663
Mok TS 2009 PFS 18.6 1217
Grønberg BH 2009 Qol 7.3 446
Pirker R 2009 OS 11.3 1100
Tan EH 2009 TTF 9.9 381
Takeda K 2009 OS 10.3 130
Fidias PM 2009 OS 12.3 309
Treat JA 2010 OS 8.7 1135
Reck M 2010 PFS 13 1043
Stathopoulos GP 2010 toxicity 10 236
Lee DH 2010 PFS 14.1 161
Takeda K 2010 OS 13.7 598
Lynch TJ 2010 PFS 9.69 676
Scagliotti G 2010 OS 10.7 926
Okamoto I 2010 OS 15.2 564
Maemondo M 2010 PFS 30.5 230
Kosmidis PA 2011 OS 11.1 398
Koch A 2011 OS 8.50 316
Gaafar RM 2011 OS 10.9 173
Hirsh V 2011 OS 10.0 828
Lara PN Jr 2011 OS 13.4 649
Table V. Results of palliative treatment of patients with NSCLC in phase III trials since 2000 (detailed data and references available from the authors)
Æ
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The first author Year Primary endpoint OS (months) Number of patients
Groen HJ 2011 OS 8.2 561
Quoix E 2011 OS 10.3 226
Coudert B 2012 PFS and TTP 11.9 889
Manegold C 2012 OS 11.0 839
Boni C 2012 OS 11.3 433
Fløtten Ø 2012 OS 7.0 444
Sun JM 2012 PFS 22.2 135
Han JY 2012 OS 22.9 309
Lee JS 2012 OS 8.5 924
Socinski MA 2012 RR 12.1 1052
Scagliotti GV 2012 OS 9.0 960
Scagliotti GV 2012 OS 13 1090
Gridelli C 2012 OS 11.6 900
Paz-Ares LG 2012 OS 12.5 904
Lee SM 2012 OS 3.7 350
Inoue A 2013 OS 27.7 228
Socinski MA 2013 RR 19.9 1052
Yoshioka H 2013 OS 15.2 564
Karampeazis A 2013 TTP ND 357
Zukin M 2013 OS 9.3 205
Sequist LV 2013 PFS 16.6 1269
Paz-Ares LG 2013 PFS 13.9 939
Barlesi F 2013 PFS 12.8 376
Johnson BE 2013 PFS 14.4 1145
Patel JD 2013 OS 13.4 939
Wu YL 2013 PFS 18.3 451
Barlesi F 2014 PFS 17.1 376
Alfonso S 2014 OS 8.23 176
Laurie SA 2014 OS 13.1 306
Yang JC 2014 PFS 27.9 253
Langer CJ 2014 OS 9.8 681
Zhou C 2015 OS 29.7 165
Wu YL 2015 PFS 26.3 217
Kubota K 2015 OS 17.1 608
Kubota K 2015 OS 20.9 227
Langer CJ 2015 RR 13.8 546
O’Brien ME 2015 OS 17.4 600
Giaccone G 2015 OS 20.3 332
Abe T 2015 OS 14.8 276
Zhou C 2015 PFS 24.3 276
Shukuya T 2015 OS 13.6 355
Thatcher N 2015 OS 11.5 1093
Paz-Ares L 2015 OS 11.5 633
Yang JC 2015 OS 33 709
OS — overall survival; PFS — progression-free survival; TTP — time to progression; RR — response rate; Qol — quality of life; ND — no data
Table V. Results of palliative treatment of patients with NSCLC in phase III trials since 2000 (detailed data and references available from the authors)
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The average number of chemotherapy cycles in the 
entire group was 3.65 (the scope was from 2 to 6 cycles). 
Only in 15 cases were more than 4 cycles were administered. 
The number of cycles was not related to the treatment regi-
men (p = 0.67). No toxic death occurred during the therapy. 
On account of toxicity, chemotherapy was postponed 105 
times (14.9% of administrations). The most frequent causes 
of chemotherapy postponement were: neutropenia (85.3% 
postponements, including neutropenic fever 1.3%), anae-
mia (6.5%), thrombocytopaenia (4.7%) and diarrhoea (3.5%). 
In 21 patients the chemotherapy dose was reduced (all the 
patients were treated with cisplatin; not counting the car-
boplatin reduction within the calculation of the area under 
the curve after an increase of creatinine levels). In 12 pa-
tients the treatment was discontinued on account of toxicity 
(11 subjects treated with cisplatin and 1 patient treated with 
carboplatin). The intensity of pain before and after treatment 
did not differ significantly (p = 0.19) and was not related to 
the response to treatment (p = 0.27). 
As the quality of life questionnaires were distributed 
among patients from January 2013 onward, this aspect 
was taken into consideration solely in 129 patients. The 
mean age in this group was 64 ± 7.9 years. The quality of 
life was not related to age, sex, place of residence or the 
treatment response. With regards to the small number of 
the subjects within the study group, the quality of life was 
not analysed separately in the subgroups receiving specific 
chemotherapy regimens. With regards to the entire group, 
during the treatment only an exacerbation of nausea and 
vomiting (p = 0.02), constipation (p < 0.01) and decrease of 
dyspnoea (p < 0.01) were observed. 
Discussion
We searched the PubMed database using such medical 
headlines as “lung tumours” and “pharmacological treat-
ment” and with the following filters: “with randomisation” 
and “third phase trial” in order to find the studies presented 
in Table V. Then we limited the search results to the pe-
riod between 1st January 2000 and 31st December 2015 in 
10 leading journals (Annals of Oncology, British Journal of 
Cancer, Cancer, Clinical Cancer Research, European Journal 
of Cancer Journal of Clinical Oncology, Journal of National 
Cancer Institute, Lancet Oncology, The Lancet and The New 
England Journal of Medicine). The documents concerning 
biological and other prognostic factors in separation from 
the main study results were excluded from the cumula-
tive breakdown, and the same concerned the trails with 
randomisation of the second phase and those based on 
adjuvant treatment. The mean survival in all listed studies 
was 12.8 months. This mean value is lower, being 9.9 months 
for the studies with the evaluation of classical chemotherapy 
(after the exclusion of the studies with inhibitors of EGFR 
tyrosine kinase inhibitors and ALK). In the material presented 
in this paper, the median overall survival was 12 months. The 
treatment results measured with the overall survival period 
in everyday clinical practice thus seem to be comparable 
with the results currently obtained in the prospective third 
phase studies.
However, these median values cannot be directly com-
pared to other patient populations. On the other hand, 
though, the majority of incidence of malignant lung cancers 
occurs after 50 years of age (96% morbidity in men and 95% 
morbidity in women), and about 50% morbidity in both 
sexes occurs in groups above 65 years of age [2]. The risk of 
lung cancer increases with age, reaching its peak in men in 
the eighth decade of life and in women at the turn of their 
sixth and seventh decade of life. The situation was very 
similar in our population in which the mean age of patients 
was 63 years. The number of patients above 75 years, much 
lower than the number of patients below 75, is probably 
the result of withholding the toxic oncological treatment 
and replacing it with palliative care in this group. Also the 
predominance of male subjects and smokers was typical for 
this type of cancer and compliant with the published data.
Our study, however, casts some light on a few prob-
lems which are significant in everyday clinical practice. The 
evaluation of our results should thus take into consideration 
some factors. First of all, the decision concerning the com-
mencement of treatment was always taken by specialists in 
clinical oncology. Their decision could have been subjective, 
but some tendencies can be observed. In the study group 
there were 27 patients above 70 years of age, including 
nine patients above 75; eight patients out of this group 
were treated with monotherapy without platin derivatives. 
A clear tendency to use monotherapy in elderly subjects 
is seen. On the other hand, though, in all these patients, 
the doctors in charge, defined the performance score as 2, 
and 90% of these patients had at least two clinical burdens 
with other serious internal diseases. Therefore, it is not very 
clear whether the decisive factors determining the choice of 
monotherapy are just the age, performance score or other 
burdens. Secondly, varied chemotherapy regimens were 
used in monotherapy: based either on cisplatin or carbo-
platin (with a significant predominance of the former). In 
a separate analysis, a significant difference with regards to 
overall survival in favour of cisplatin was shown. A limitation 
of this comparison is the relatively low number of patients 
receiving various treatment regimens based on carboplatin 
(n = 33). Thirdly, the analysis showed the significant influ-
ence of the performance status and the age of patients on 
their overall survival, which was also observed in the clini-
cal studies addressed for the patients in older age groups 
[22, 23]. Our study also has a few potential drawbacks. The 
most important one is its retrospective character. The lack 
of significant differences in the overall survival period for di-
verse histological subtypes of non-small cell lung carcinoma 
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may be explained by the lack of administration of different 
treatment schemes for adenocarcinoma. In our case, only 
21 subjects in the first line of chemotherapy were treated 
with pemetrexed and 8 with EGFR inhibitors. This was partly 
the result of the period in which the studies were carried 
out, as, at this point, pemetrexed was refunded only in the 
second line of treatment (in this period, 34 patients with 
a diagnosis of adenocarcinoma began the first line of ther-
apy). Moreover, a large group of patients did not meet the 
criteria of the National Health Fund Programme. In the ana-
lysed population, out of the patients qualified for treatment 
with the use of pemetrexed, as many as 12 patients had 
contraindications for cisplatin, 7 patients refused to com-
mute 35 kilometres to the centres which had the possibility 
of administering cisplatin, 5 patients had brain metastases 
and in 3 cases some abnormalities in laboratory tests were 
found, which did not meet the criteria for the inclusion to 
the therapy; in 2 cases the performance score was PS = 2, in 
2 other cases, there were cardiovascular contraindications 
and in 1 case the cause remained unknown. A low share of 
the patients with the EGFR gene mutation is also surpris-
ing (10 cases out of 204 patients — less than 5%). In the 
Polish population, the rat of this mutation carriers is about 
8.4% [24]. The causes for this phenomenon, and especially 
discrepancies between the centres remain unknown (for 
Wejherowo, this share was only 3.2%). This may be the out-
come of the different population profile of patients treated 
there, as in that centre the dominating group of patients 
were men, smoking cigarettes or other forms of tobacco 
users (this was pipe smoking or snuff usage, characteristic 
for Kashubia). The outcome of this fact may be a low rate of 
patients treated with anti-EGFR therapies which could affect 
the obtained results.
In the discussed material, in 5.8% cases, the treatment 
was discontinued on account of toxicity and in 10.3% the 
chemotherapy doses were reduced. In 33 cases at least two 
serious toxicity complications were found. The toxicity data 
presented here may be, however, underestimated, with 
regards to the retrospective character of the study. Only 
in 8 patients (3.9%) was hospitalisation during the therapy 
necessary. In all the cases this was connected with anaemia 
requiring the transfusion of packed red blood cells. These 
results show that palliative chemotherapy in lung cancer 
patients may be carried out on an outpatient basis in the 
majority of cases. It must be stressed that in the majority of 
patients, the secondary prophylaxis was applied with the 
use of granulocyte growth factors, which decreased the risk 
of clinically significant neutropenia after the first incident 
of this type of complication
The larger toxicity of cisplatin-based chemotherapy is 
complaint with the published data [25, 26]. Carboplatin 
was introduced into clinical studies at the beginning of the 
1980s as an agent with a similar activity to cisplatin, yet 
with a different toxicity profile, comprising bone marrow 
suppression but with a significantly lower nephrotoxicity 
and neurotoxicity and much less emetogenic [25]. There is 
a widely held conviction that carboplatin is better tolerated 
than cisplatin. The presented data and their interpreta-
tion confirm our hypothesis that the toxicity of treatment 
observed in everyday clinical practice may be higher than 
the results obtained in the clinical studies; doctors, fearing 
this toxicity, may decide to choose carboplatin, which, in 
our study turned out to be the agent with a smaller share 
of serious toxicities. Those results, however, cannot be 
compared, as the populations of patients treated with 
cisplatin and carboplatin did not differ significantly from 
one another. In the population treated with carboplatin, 
the mean age was higher and the co-morbidities were 
more frequent. This does not change the fact that carbo-
platin was a drug that was better tolerated, with a smaller 
emetogenic and nephrotoxic potential, yet it was also 
less effective with regards to the treatment response and 
overall survival.
In our material the first line of palliative chemotherapy 
in lung cancer did not have any significant influence on the 
general quality of life. We have already shown in previous 
studies that the systemic treatment frequently does not 
affect the quality of life of the patients with NSCLC [27]. 
Moreover, during the therapy, in the entire group of patients, 
an increase of nausea and vomiting and constipation cases 
was observed, yet also a reduction of dyspnoea. 
Conclusions 
The presented conclusions suggest that the efficiency of 
palliative treatment of the patients with non-small cell lung 
carcinoma in everyday clinical practice may be comparable 
with the efficiency obtained in the clinical studies with clas-
sical chemotherapeutic agents and platin derivatives differ 
from each other not only with their toxicity profile, but also 
with clinical efficiency. This conclusion, however, should be 
verified in a well-designed observational trial. 
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